Glenmark Pharmaceuticals Ltd. – Product Pipeline Review – Q2 2011 by GlobalMarketsDirect

VIEWS: 6 PAGES: 66

More Info
									      Glenmark Pharmaceuticals Ltd. – Product Pipeline
                    Review – Q2 2011
                                                                                          Reference Code: GMDHC1321CDB

                                                                                                Publication Date: JUL 2011




Glenmark Pharmaceuticals Ltd. – Product Pipeline Review – Q2 2011                           GMDHC1321CDB / Published JUL 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                Page(1)
Glenmark Pharmaceuticals Ltd. – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents                                                                                                     2
List of Tables                                                                                                        4
List of Figures                                                                                                       5
Glenmark Pharmaceuticals Ltd. Snapshot                                                                                6
    Glenmark Pharmaceuticals Ltd. Overview                                                                            6
    Key Information                                                                                                   6
    Key Facts                                                                                                         6
Glenmark Pharmaceuticals Ltd. – Research and Development Overview                                                     7
    Key Therapeutic Areas                                                                                             7
Glenmark Pharmaceuticals Ltd. – Pipeline Review                                                                      10
    Pipeline Products by Stage of Development                                                                        10
    Pipeline Products – Monotherapy                                                                                  11
Glenmark Pharmaceuticals Ltd. – Pipeline Products Glance                                                             12
    Glenmark Pharmaceuticals Ltd. Clinical Stage Pipeline Products                                                   12
         Phase II Products/Combination Treatment Modalities                                                          12
         Phase I Products/Combination Treatment Modalities                                                           13
    Glenmark Pharmaceuticals Ltd.–Early Stage Pipeline Products                                                      14
         Pre-Clinical Products/Combination Treatment Modalities                                                      14
Glenmark Pharmaceuticals Ltd. – Drug Profiles                                                                        15
    GRC 6211                                                                                                         15
         Product Description                                                                                         15
         Mechanism of Action                                                                                         15
         R&D Progress                                                                                                15
    Melogliptin                                                                                                      17
         Product Description                                                                                         17
         Mechanism of Action                                                                                         17
         R&D Progress                                                                                                17
    Oglemilast                                                                                                       18
         Product Description                                                                                         18
         Mechanism of Action                                                                                         18
         R&D Progress                                                                                                18
    TRPV1 Antagonist                                                                                                 20
         Product Description                                                                                         20
         Mechanism of Action                                                                                         20
         R&D Progress                                                                                                20
    GRC 10693                                                                                                        21
         Product Description                                                                                         21
         Mechanism of Action                                                                                         21
         R&D Progress                                                                                                21
    GRC 15300                                                                                                        22
         Product Description                                                                                         22
         Mechanism of Action                                                                                         22
         R&D Progress                                                                                                22
    GRC 4039                                                                                                         24
         Product Description                                                                                         24
         Mechanism of Action                                                                                         24




Glenmark Pharmaceuticals Ltd. – Product Pipeline Review – Q2 2011                         GMDHC1321CDB / Published JUL 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                             Page(2)
Glenmark Pharmaceuticals Ltd. – Product Pipeline Review



         R&D Progress                                                                                                           24
    GBR 600                                                                                                                     25
         Product Description                                                                                                    25
         Mechanism of Action                                                                                                    25
         R&D Progress                                                                                                           25
    GBR 900                                                                                                                     26
         Product Description                                                                                                    26
         Mechanism of Action                                                                                                    26
         R&D Progress                                                                                                           26
    GRC 9332                                                                                                                    27
         Product Description                                                                                                    27
         Mechanism of Action                                                                                                    27
         R&D Progress                                                                                                           27
Glenmark Pharmaceuticals Ltd. – Pipeline Analysis                                                                               28
    Glenmark Pharmaceuticals Ltd. – Pipeline Products by Therapeutic Class                                                      28
    Glenmark Pharmaceuticals Ltd. - Pipeline Products By Target                                                                 29
    Glenmark Pharmaceuticals Ltd. – Pipeline Products by Route of Administration                                                30
    Glenmark Pharmaceuticals Ltd. – Pipeline Products by Molecule Type                                                          31
Glenmark Pharmaceuticals Ltd. – Recent Pipeline Updates                                                                         32
Glenmark Pharmaceuticals Ltd. - Dormant Projects                                                                                34
Glenmark Pharmaceuticals Ltd. – Company Statement                                                                               35
Glenmark Pharmaceuticals Ltd. – Locations And Subsidiaries                                                                      37
    Head Office                                                                                                                 37
    Other Locations & Subsidiaries                                                                                              37
Financial Deals Landscape                                                                                                       39
    Glenmark Pharmaceuticals Ltd., Deals Volume Summary, 2004 to YTD 2011                                                       39
    Glenmark Pharmaceuticals Ltd., Deals Summary By Region, 2004 to YTD 2011                                                    40
    Glenmark Pharmaceuticals Ltd., Deals Summary, 2004 to YTD 2011                                                              41
    Glenmark Pharmaceuticals Ltd. Detailed Deal Summary                                                                         43
         Asset Purchase                                                                                                         43
         Actavis Sells 7 Products In Poland To Glenmark Pharmaceuticals                                                         43
         Glenmark Farmaceutica Acquires Uno-Ciclo From Instituto Biochimico Industria Farmaceutica                              44
         Acquisition                                                                                                            45
         Glenmark Pharmaceuticals Acquires Majority Stake In Medicamenta                                                        45
         Glenmark Pharmaceuticals Acquires Laboratorios Klinger                                                                 46
         Private Equity                                                                                                         47
         Paul Capital Invests $27 Million In Glenmark Pharmaceuticals                                                           47
         Equity Offering                                                                                                        49
         Glenmark Pharmaceuticals Completes Private Placement Of $88 Million                                                    49
         Debt Offering                                                                                                          52
         Glenmark Pharmaceuticals Completes Convertible Bond Offering Of $30 Million                                            52
         Glenmark Pharmaceuticals Completes Zero Coupon Equity-linked Securities Bonds Offering Of $50 Million                  54
         Glenmark Pharmaceuticals Completes Zero Coupon Convertible Bonds Offering Of $20 Million                               55
         Glenmark Pharmaceuticals Enters Into Agreement With MeyerZall Laboratories                                             56
         Glenmark Pharmaceuticals Enters Into Agreement With Lehigh Valley Technologies                                         57
         Glenmark Pharmaceutical Enters Into Agreement With Merck Generics                                                      58
         Glenmark Pharmaceuticals Enters Into Agreement With Shasun Chemicals & Drugs                                           59
         Licensing Agreements                                                                                                   60




Glenmark Pharmaceuticals Ltd. – Product Pipeline Review – Q2 2011                                    GMDHC1321CDB / Published JUL 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                        Page(3)
Glenmark Pharmaceuticals Ltd. – Product Pipeline Review



         Glenmark Enters Into In-Licensing Agreement With Stratpharma                                                             60
         Glenmark Pharmaceuticals Enters Into Licensing Agreement With Medicis Pharmaceutical                                     61
         Glenmark Pharmaceuticals Enters Into A Collaboration Agreement With InvaGen Pharmaceuticals                              63
         Glenmark Pharmaceuticals Partners With Napo Pharmaceuticals                                                              64
Appendix                                                                                                                          65
    Methodology                                                                                                                   65
         Coverage                                                                                                                 65
         Secondary Research                                                                                                       65
         Primary Research                                                                                                         65
         Expert Panel Validation                   
								
To top